MYD88 mutation detection PCR

Alphabetical Test listing

MYD88 mutation detection PCR-994

MYD88 mutation detection PCR
MYD88 Mutation Detection PCR

The presence of MYD88 (L265P) mutations aids in differential diagnosis of certain lymphomas, most commonly lymphoplasmacytic lymphoma (LPL) / Waldenstrom’s Macroglobulinemia (WM). Patients diagnosed with LPL/WM may benefit from certain therapeutic options. Also relevant to diffuse large B cell lymphoma (particularly CNS and testicular DLBCL) and IgM MGUS.

EDTA whole blood
5 mL
3.0 mL

Lavender (EDTA), 4mL


Sodium heparin (Na hep) whole blood
Bone marrow
pPraffin-embedded tissue slides
Whole blood - 5 mL (minimum 3mL)
Bone marrow - 1 mL (minimum 200 µL)
Tissue slides - two (2) 10 micron (minimum 1 ten micron) or four (4) (minimum 2) five micron thick slides

Dk green Sodium heparin (Na hep), no gel

Sterile container

Slide holder


Refrigerated (preferred) - 7 days

Ambient - 48 hours

  • PCR testing cannot be added on to a sample that has been opened and/or used for other testing. If the sample has already been used for testing, a new specimen will need to be collected.
LabCorp Integrated Oncology (115005): R-NX
Mo, We, Fr
4 days

Polymerase chain reaction (PCR)


An interpretive report will be provided


The myeloid differentiation primary response 88 gene (MYD88) encodes for a signal transducer protein which plays a vital role of innate immune response. The MYD88 L265P mutation, which is the most common mutation, is detected by allele specific PCR technique in ~86‐100% cases of lymphoplasmacytic lymphoma (LPL)/Waldernstrom Macroglobulinemia (WM) and >40% of IgM MGUS, but is absent in IgM myeloma. In addition, ~ 30% of activated B‐cell-like (ABC) subtype of diffuse large B‐cell lymphoma (DLBCL) contain this mutation compared to <10% cases of the germinal center B‐cell‐like (GCB) subtype. However, this mutation is found in over 80% of DLBCL in testes and >50% of primary CNS DLBCL. This mutation is only rarely observed in marginal zone lymphoma with positive cases typically representing splenic marginal zone lymphoma with monoclonal IgM paraproteinemia. The mutation is rarely detected in other hematopoietic malignancies.